Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies

The report says about 44% of 2025's disclosed total went into larger rounds for a smaller group of companies. It describes these firms as capitalized with enough reserve to pivot to another asset if the first one stalls. Founders seeking true seed money, under $5 million, face a harder market, according to the report.

The likely driver is the buyer. Longevity.Technology has argued that Big Pharma tends to buy proven science rather than build it. If so, venture investors have reason to fund proven science too. The report is careful on this point. It calls the pattern consistent with "reverse capture" rather than proven by it. Longevity.Technology's own commentary stresses that the data show capital relocating, not vanishing.

Fund economics add pressure. Hugh Rienhoff, a biotech entrepreneur and investor, argues in the Financial Times that many biotech venture investors have become bankers who chase deals and exits. That is one investor's argument, not a finding. He points to PitchBook data showing general biotech fundraising fell from a $152.3 billion peak in 2018 to $12 billion in 2024. Drug development still takes more than 15 years. Faster returns therefore tend to mean backing assets that are already validated.

Cellular reprogramming is the exception. The report calls it the hot category across specialist, generalist and pharma-linked investors. NewLimit raised $610 million across three rounds. Retro Biosciences raised roughly $1 billion in a single Series A. Crossover and tech-native funds, including Founders Fund, Thrive, a16z, General Catalyst and Accel, now write the largest checks. Lilly Ventures also sits in NewLimit's rounds.

The report describes a relay. Specialist funds such as Apollo Health Ventures, age1, Kizoo and Hevolution originate seed and Series A deals. For example, age1 co-led a $21 million seed round in Aerska, then co-led a $39 million Series A four months later. Generalists lead at scale. Pharma venture arms come in once risk has fallen. Hevolution's more than $400 million in grant commitments now sits alongside a growing run of lead equity positions.

NewLimit, Aeovian, Juvena and TRIMTECH each drew money from two or all three investor groups. The report reads this as the strongest early sign that pharma uses corporate venture as a scouting tool. That is the report's interpretation. The evidence is deal data, and the report was sponsored by MuseCell Innovations.

For the market, the implication is a gap at the earliest and riskiest stage, with fewer hands holding seed risk. Founders may need to plan early for who takes the next handoff. Watch whether 2026 totals keep rising while seed-stage rounds stay scarce, and whether more pharma venture arms appear in early deals.

Longevity Funding Nearly Quadruples as Investors Concentrate on Fewer, Later-Stage Companies Fractyl Cuts 45% of Staff to Focus on Revita After Pivotal Win CMS and States Launch $275M Program to Recruit Nursing Home Nurses Insurers Split on How the Pandemic Should Shape Future Mortality Assumptions Owners Reportedly Explore $1 Billion Sale of Largest US Senior Living Operator